



Review Effect of Intravenous Ketamine on Hypocranial Pressure Symptoms in Patients with Spinal Anesthetic Cesarean Sections: A Systematic Review and Meta-Analysis

Xiaoshen Liang¹, Xin Yang¹, Shuang Liang¹, Yu Zhang¹, Zhuofeng Ding¹, Qulian Guo^{1,2} and Changsheng Huang^{1,2,*}

- ¹ Department of Anesthesiology, Xiangya Hospital Central South University, Changsha 410008, China; 198112351@csu.edu.cn (X.L.); doctorxinyang@hotmail.com (X.Y.); liangshuang@csu.edu.cn (S.L.); zhangy20210618@163.com (Y.Z.); dzfzhuofeng@163.com (Z.D.); qulianguo@hotmail.com (Q.G.)
- ² National Clinical Research Center for Geriatric Disorders, Xiangya Central South University, Changsha 410008, China
- * Correspondence: changsheng.huang@csu.edu.cn; Tel./Fax: +86-731-84327413

Abstract: Background: Pregnant women are more likely to suffer post-puncture symptoms such as headaches and nausea due to the outflow of cerebrospinal fluid after spinal anesthesia. Because ketamine has the effect of raising intracranial pressure, it may be able to improve the symptoms of perioperative hypocranial pressure and effectively prevent the occurrence of hypocranial pressure-related side effects. Method: Keywords such as ketamine, cesarean section, and spinal anesthesia were searched in databases including Medline, Embase, Web of Science, and Cochrane from 1976 to 2021. Thirteen randomized controlled trials were selected for the meta-analysis. Results: A total of 12 randomized trials involving 2099 participants fulfilled the inclusion criteria. There was no significant association between ketamine and the risk of headaches compared to the placebo (RR = 1.12; 95% CI: 0.53, 2.35; p = 0.77; $I^2 = 62\%$). There was no significant association between ketamine or the placebo and vomiting were found (RR = 0.94; 95% CI: 0.53, 1.67; p = 0.83; $I^2 = 72\%$). Conclusion: Intravenous ketamine does not improve the symptoms caused by low intracranial pressure after spinal anesthesia in patients undergoing cesarean section.

Keywords: cesarean section; ketamine; spinal anesthesia; intracranial hypotension; post-dural puncture headache

1. Introduction

The proportion of cesarean sections in deliveries is increasing due to the gradual maturation of birth assistance techniques and social factors [1,2]. Cesarean delivery can help pregnant women who are not allowed to deliver normally due to problems such as pelvic stenosis, uterine opening insufficiency, and placenta previa, as well as avoiding the occurrence of pelvic floor injury, urinary incontinence, vaginal relaxation and other complications caused by natural labor [3,4]. However, weight gain during pregnancy leads to subcutaneous fat thickening and unclear exposure between vertebrae, which inevitably increases the risk of spinal anesthesia and post-puncture complications [5]. Hypocranial pressure caused by cerebrospinal fluid outflow is one of the common complications after spinal anesthesia, mainly manifested as headache after dural puncture [6], especially in terms of obstetric anesthesia [7]. In addition, low intracranial pressure cause nausea and vomiting [8]. Ketamine is known as a non-competitive, high-affinity N-methyl-D-aspartic acid (NMDA) receptor antagonist. Unlike sedative drugs such as propofol and etomidate, it also has a good analgesic effect, which has led to its common use in postoperative



Citation: Liang, X.; Yang, X.; Liang, S.; Zhang, Y.; Ding, Z.; Guo, Q.; Huang, C. Effect of Intravenous Ketamine on Hypocranial Pressure Symptoms in Patients with Spinal Anesthetic Cesarean Sections: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 4129. https://doi.org/10.3390/ jcm11144129

Academic Editors: Marco Cascella and Cyrus Motamed

Received: 5 June 2022 Accepted: 11 July 2022 Published: 16 July 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). analgesia in patients undergoing surgery [9]. Another characteristic of ketamine is that it can increase the intracranial pressure [10,11], and by this compensatory effect, it can relieve headaches caused by low intracranial pressure [12]. However, evidence from other studies is inconsistent regarding whether ketamine reduces the incidence of headaches in patients undergoing cesarean delivery. Therefore, as evidence accumulated, we integrated relevant randomized controlled trials (RCTs) and performed a systematic review and meta-analysis to assess whether ketamine reduced the incidence of headaches in patients undergoing cesarean section under spinal anesthesia. Herein, we hypothesize that ketamine may be an effective agent for the prevention of hypocranial pressure syndrome. We hope to provide evidence for the value of ketamine in the prevention of headaches caused by low cranial pressure.

2. Materials and Methods

2.1. Search Strategy and Selection Criteria

This study was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the Medline, Embase, Web of Science, and Cochrane databases from 1976 to 2021 (search strategies are detailed in Appendix A), resulting in the inclusion of 2099 patients. The search policy was designed and executed by two authors (Xing, Yang, and Shuang, Liang).

The inclusion criteria were as follows: (a) randomized controlled trial; (b) American Society of Anesthesiologists (ASA) I–II; (c) patient undergoing cesarean section with spinal anesthesia; (d) participant treated intravenously with ketamine; (e) article written in English. The exclusion criteria were as follows: (a) unpublished clinical trial; (b) full text unavailable; (c) control group received a drug other than normal saline.

2.2. Data Extraction and Quality Assessment

The data included in each study were independently extracted by two researchers and summarized in an Excel spreadsheet (Xiaoshen Liang and Yu Zhang). We extracted the following information from these studies: the first author's name, year of publication, number of patients, age, BMI (height and weight values were provided in some studies), ketamine dose, needle size, relevant outcomes (the incidence of perioperative headaches, nausea, and vomiting), and reported results. This analysis assessed the outcomes, including the incidence of perioperative headaches, nausea, and vomiting, which are clinical manifestations of low cranial pressure (Table 1). Two other investigators (Xing, Yang, and Shuang, Liang) independently evaluated the included studies according to the Cochrane Handbook for Systematic Reviews of Interventions 5.0. The specific contents of the assessment's "risk of bias" table included the following: adequate sequence generation, allocation of concealment, blinding, incomplete outcome data, free of selective reporting, and free of other bias.

2.3. Statistical Analysis

We evaluated the dichotomous data using risk ratios with 95% confidence intervals. Heterogeneity is reported using I² statistics; I² > 50% indicates significant heterogeneity. When there was significant heterogeneity between the two included studies (p < 0.05 or I² > 50%), the size of the combined effect was calculated using the random-effects model; otherwise, the fixed-effects model was used. If significant heterogeneity existed, we omitted a study and instead looked for potential sources of heterogeneity. We also performed heterogeneity analysis by subgroup analysis. A leave-one-out test, consisting of calculating the pooled risk ratio by sequentially excluding one study, was performed to identify studies with a strong influence on the results. The publication bias was assessed by using funnel plots. Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK) was used to perform the meta-analyses. *p*-Values <0.05 were considered statistically significant.

First Author	Year	Number (K; C)	Age, Years (K; C)	BMI	Height, cm (K; C)	Weight, kg (K; C)	Surgery Time, min (K; C)	Ketamine Dose (mg/kg)	Needle Size (G)	Relevant Outcomes	Reported Results (K; C)
Sen, S. et al. [13].	2005	30; 30	$\begin{array}{c} 26.3 \pm 5.3; \\ 27.1 \pm 4.6 \end{array}$	/	$\begin{array}{c} 162 \pm 6.1; \\ 160.0 \pm 5.2 \end{array}$	$78.1 \pm 7.8; \\73.2 \pm 9.4$	$\begin{array}{c} 41.9 \pm 9.2; \\ 48.3 \pm 6.4 \end{array}$	0.15	25	Headache, nausea	1. Headache 2; 5 2. Nausea 2; 3
Menkiti, I. D. et al. [14].	2012	28; 28	$\begin{array}{c} 30.3 \pm 4.0; \\ 29.8 \pm 3.1 \end{array}$	/	$\begin{array}{c} 1.64 \pm 0.03; \\ 1.61 \pm 0.12 \end{array}$	$\begin{array}{c} 73.7 \pm 6.2; \\ 72.2 \pm 5.0 \end{array}$	$56.3 \pm 8.6;$ 55.6 ± 8.6	0.15	26	Headaches, nausea, and vomiting	1. Headaches 1; 1 2. Nausea 0; 2 3. Vomiting 2; 1
Rahmanian, M. et al. [15].	2015	80; 80	$\begin{array}{c} 27.4 \pm 4.8; \\ 27.6 \pm 4.4 \end{array}$	/	/	$78.5 \pm \\11.9; \\77.7 \pm 10.8$	$\begin{array}{c} 40.2 \pm 3.8;\\ 39.8 \pm 3.2 \end{array}$	0.25	25	Headaches, nausea, and vomiting	1. Headaches 21; 27 2. Nausea 26; 25 3. Vomiting 15; 28
Edipoglu, I. S. et al. [16].	2017	60; 60	$\begin{array}{c} 28.68 \pm 5.82; \\ 28.43 \pm 4.82 \end{array}$	$\begin{array}{c} 33.54 \pm 4.61; \\ 33.85 \pm 4.94 \end{array}$	/	/	$\begin{array}{c} 27.30 \pm 7.36;\\ 27.93 \pm 5.34 \end{array}$	0.15	26	Headaches, nausea, and vomiting	1. Headaches 0; 2 2. Nausea 2; 11 3. Vomiting 2; 11
Xu, Y. et al. [17].	2017	162; 163	$\begin{array}{c} 31\pm4;\\ 32\pm4 \end{array}$	$\begin{array}{c} 27\pm3;\\ 28\pm3 \end{array}$	/	/	$\begin{array}{c} 43.8 \pm 14.4; \\ 44.0 \pm 12.6 \end{array}$	0.25	25	Headaches and vomiting	1. Headaches 8; 1 2. Vomiting 7; 2
Zangouei, A. et al. [12].	2019	32; 32	/	/	/	/	/	0.15	27	Headaches	1. Headaches 10; 14
Yao, J. et al. [18].	2020	153; 155	$30 \pm 4;$ 30 ± 3	$29 \pm 3;$ 28 ± 3	/	/	/	0.25	/	Headaches	1. Headache 15; 3
Kose, E. A. et al. [19].	2013	(30 + 30); 30	{28.2 (18–43) + 26.8 (20–45)}; 27.3 (18–43)	$\begin{array}{c} \{ 26.9 \pm 5.9 \\ + \ 26.3 \pm 6.1 \}; \\ 27.8 \pm 6.8 \end{array}$	/	/	$68 \pm 6;$ 71 ± 5; 65 ± 7	0.25 and 0.5	25	Nausea and vomiting	1. Nausea 10; 13 2. Vomiting 5; 6
Hassanein, A. et al. [20].	2015	45; 45	$\begin{array}{c} 29.4 \pm 7.2; \\ 30 \pm 6 \end{array}$	/	$\begin{array}{c} 163\pm4;\\ 162\pm6.5\end{array}$	$\begin{array}{c} 72\pm9;\\ 69\pm13 \end{array}$	/	0.4	25	Nausea and vomiting	1. Nausea 6; 13 2. Vomiting 4; 9
Lema, G. F. et al. [21].	2017	41; 41	26 (6); 26 (7)	/	160 (10); 160 (11)	60 (9); 60 (14)	50 (20); 45 (20)	0.2	22–25	Nausea and vomiting	1. Nausea 5; 6 2. Vomiting 5; 6
Ma, J. H. et al. [22].	2019	327; 327	/	$27.5 \pm 3.1;$ 29.4 ± 26.6	/	/	/	0.5	25	Vomiting	1. Vomiting 62; 30
Sarshivi, F. et al. [23].	2020	45; 45	30.8 (±4.5); 29.8 (±4.5)	$29.4 \pm 3.3;$ 29.1 ± 8.8	$\begin{array}{c} 159.12 \pm 4.52; \\ 158.14 \pm 4.22 \end{array}$	$68.19 \pm 5.48; 67.37 \pm 8.12$	51 (±18); 54 (±15)	0.3	25	Nausea and vomiting	1. Nausea 18; 12 2. Vomiting 14; 8

Table 1. Characteristics of the included studies.

Table notes: K, ketamine group; C, control group; BMI, body mass index.

3. Results

3.1. Eligible Studies and the Characteristics

By searching the databases mentioned above, 208 studies were retrieved for the systematic review. Eighty-seven duplicate studies were excluded. After screening the titles and abstracts, only thirty studies were considered eligible for full reading. Twelve studies met all the selection criteria [12–23] as determined through browsing the titles, abstracts, and full texts (Figure 1). The included articles were published between 2005 and 2020, with sample sizes ranging from 28 to 163. All of the patients were delivered by cesarean section under spinal anesthesia and injected with ketamine intravenously at 0.15–0.5 mg/kg. The baseline characteristics of all the studies were statistically similar. The characteristics of the included randomized controlled trials are summarized below (Table 1).

Of all the included studies, three documented the incidence of postoperative headaches at different time points; the remaining studies did not explain the specific time points of occurrence. Therefore, the number with the highest incidence in these studies was chosen as the overall incidence figure based on the authors' description of the recording method. One study used two doses of ketamine compared to a placebo group, so we combined the two into one group when extracting data. In all the included articles, we could only calculate the respective totals of postoperative headaches, nausea, and vomiting in each study, as most articles did not include headaches, nausea, or vomiting as primary outcomes. Only one study [12] documented, in detail, the incidence of headaches occurring immediately postoperatively, 4 h postoperatively, 12 h postoperatively, and 24 h postoperatively. And in this study, a significant difference was found in the incidence of headaches between the ketamine and control groups in the immediate postoperative period and 4 h postoperatively, while no significant difference was found in the 12-h and 24-h postoperative periods. However, in another study [18], who recorded the incidence of headaches at 5 min

postoperatively, 15 min postoperatively, and at the time of leaving the operating room, the incidence of headaches was higher in the ketamine group than in the control group.




Figure 1. Flow diagram of the study selection.


3.2. Quality Assessment of the Selected Studies

The Cochrane Quality Assessment Form indicated that the majority of the studies were regarded as "low risk" or "unclear risk". The risk after consolidation is shown in Figure 2.


3.3. Effect of Interventions

3.3.1. Headaches

The incidence of postoperative headaches was assessed in this meta-analysis. Considering the significant heterogeneity ($I^2 > 50\%$), we used the random-effects model to calculate the pooled effect size. There was no significant improvement in the ketamine group compared to the placebo (RR = 1.12; 95% CI: 0.53, 2.35; p = 0.77; $I^2 = 62\%$) (Figure 3).







(b)

	Ketam	nine	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Edipoglu, I. S 2017	0	60	2	60	5.1%	0.20 [0.01, 4.08]	· · · · · · · · · · · · · · · · · · ·
Menkiti, I. D 2012	1	28	1	28	6.0%	1.00 [0.07, 15.21]	
Rahmanian, M 2015	21	80	27	80	26.3%	0.78 [0.48, 1.26]	
Sen, S 2005	2	30	5	30	12.9%	0.40 [0.08, 1.90]	
Xu, Y 2017	8	162	1	163	9.0%	8.05 [1.02, 63.63]	
Yao, J 2020	15	153	3	155	16.5%	5.07 [1.50, 17.15]	_
Zangouei, A 2019	10	32	14	32	24.2%	0.71 [0.37, 1.36]	
Total (95% CI)		545		548	100.0%	1.12 [0.53, 2.35]	-
Total events	57		53				
Heterogeneity: Tau ² =				(P = 0.0	l1); l² = 62	2%	
Test for overall effect: J	Z = 0.29 (I	P = 0.71	7)				Favours [experimental] Favours [control]

Figure 3. Forest plot of headaches [12–18].

3.3.2. Nausea

The incidence of postoperative nausea was assessed in this meta-analysis. We used the random-effects model to calculate the pooled effect size. The nausea was not significantly different between the two groups (RR = 0.66; 95% CI: 0.40, 1.09; p = 0.10; $I^2 = 57\%$) (Figure 4).

	Ketam	ine	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Edipoglu, I. S 2017	2	60	11	60	8.0%	0.18 [0.04, 0.79]	
Hassanein, A. 2015	6	45	13	45	14.4%	0.46 [0.19, 1.11]	
Kose,E.A 2013	10	60	13	30	17.2%	0.38 [0.19, 0.77]	_
Lema, G. F.,2017	5	41	6	41	11.4%	0.83 [0.28, 2.52]	
Menkiti, I. D 2012	0	28	2	28	2.5%	0.20 [0.01, 3.99]	
Rahmanian, M 2015	26	80	25	80	21.3%	1.04 [0.66, 1.64]	
Sarshivi, F2020	18	45	12	45	18.8%	1.50 [0.82, 2.74]	
Sen, S 2005	2	30	3	30	6.4%	0.67 [0.12, 3.71]	
Total (95% CI)		389		359	100.0%	0.66 [0.40, 1.09]	•
Total events	69		85				
Heterogeneity: Tau ² =	0.25; Chi⁼	²= 16.3	1, df = 7 (P = 0.0	l2); l² = 57	'%	
Test for overall effect: 2	Z = 1.63 (F	^o = 0.10))				0.01 0.1 1 10 100 Favours [experimental] Favours [control]

Figure 4. Forest plot of nausea [13–16,19–21,23].

3.3.3. Vomiting

The incidence of postoperative vomiting was assessed in this meta-analysis. We used the random-effects model to calculate the pooled effect size. Vomiting was not significantly different between the two groups (RR = 0.94; 95% CI: 0.53, 1.67; p = 0.83; I² = 72%) (Figure 5).




Figure 5. Forest plot of vomiting [14–23].

3.4. Subgroup Analysis

Considering that different durations of ketamine administration may be one of the important factors affecting the outcome indicators, we conducted a subgroup analysis of the included studies, which were divided into two subgroups: pre-delivery administration and post-delivery administration. However, the results of the three outcome measures did not change, and there was still no significant difference between the ketamine and control groups (Figure 6a–c).

3.5. Sensitivity Analysis and Publication Bias

In sensitivity analyses, we calculated the combined effect size by the consecutive exclusion of one study, but the indicators remained non-significantly different between the two groups, indicating that our primary estimates of headaches, nausea, and vomiting were robust. No obvious publication bias was found through the visual inspection of the funnel plots (Figure 7a–c).

Study or Subgroup		10	Contro			Risk Ratio	Risk Ratio	
		Total I	vents	Total	Weight M	-H, Random, 95% Cl	M-H, Random, 95% Cl	
2.1.1 Injection before d								
/lenkiti, I. D 2012	1	28	1	28	6.0%	1.00 [0.07, 15.21]		
Sen, S 2005	2	30	5	30	12.9%	0.40 [0.08, 1.90]		
Cangouei, A 2019 Subtotal (95% Cl)	10	32 90	14	32 90	24.2% 43.0%	0.71 [0.37, 1.36] 0.67 [0.37, 1.20]	.	
otal events	13	90	20	90	43.070	0.07 [0.37, 1.20]	-	
leterogeneity: Tau² = 0		: 0.55 c		= 0.76	: I² = 0%			
est for overall effect: Z			a-2() ·	- 0.1 0,	,1 = 0.0			
.1.2 Injection after del	ivery							
dipoglu, I. S 2017	0	60	2	60	5.1%	0.20 [0.01, 4.08]	· · · · ·	
Rahmanian, M 2015	21	80	27	80	26.3%	0.78 [0.48, 1.26]		
(u, Y 2017	8	162	1	163	9.0%	8.05 [1.02, 63.63]		
ao, J 2020	15	153	3	155	16.5%	5.07 [1.50, 17.15]		
ubtotal (95% CI)	44	455	33	458	57.0%	1.81 [0.40, 8.13]		
'otal events leterogeneity: Tau² = 1 'est for overall effect: Z	.63; Chi ² =			9 = 0.01	03); I² = 78%	6		
otal (95% CI)		545		548	100.0%	1.12 [0.53, 2.35]	•	
otal events	57		53			112 [0.33, 2.33]	, , T ,	
leterogeneity: Tau² = 0 est for overall effect: Z			dt = 6 (H	' = 0.01	l); l*= 62%		0.01 0.1 1 10 Favours (ketamine) Favours (contro	
est for subaroup differ	ences: Ch	ni² = 1.4	7. df = 1	(P = 0.	22). I ² = 32.:		ravours (ketannine) ir avours (conuc	/I
	Kotami		Contr	al		(a) Dick Patio	Dick Datio	
tudy or Subgroup			Contr Events		Weight I	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% Cl	
.1.1 Injection before a								
lassanein, A. 2015	6	45	13	45	15.2%	0.46 [0.19, 1.11]		
(ose,E.A 2013	10	30	13	30	15.2%	0.77 [0.40, 1.47]		
.ema, G. F.,2017	5	41	6	41	7.0%	0.83 [0.28, 2.52]		
1enkiti, I. D 2012	0	28	2	28	2.9%	0.20 [0.01, 3.99]		
Sen, S 2005	2	30	3	30	3.5%	0.67 [0.12, 3.71]		
Subtotal (95% CI)	22	174	27	174	43.9%	0.63 [0.40, 0.99]	-	
iotal events leterogeneity: Chi² = 1	23 67 df - 4	(P = 0	37 	n 04.				
est for overall effect: Z				0.00				
.1.2 Injection after de	-							
dipoglu, I. S 2017	2	60	11	60	12.9%	0.18 [0.04, 0.79]		
ahmanian, M 2015	26	80	25	80	29.2%	1.04 [0.66, 1.64]		
Sarshivi, F2020	18	45 185	12	45 185	14.0% 56.1 %	1.50 [0.82, 2.74]	_	
oubtotal (95% CI) otal events	46	105	48	105	50.1%	0.96 [0.68, 1.35]	T	
leterogeneity: Chi ² = 7		P(P = 0)		72%				
est for overall effect: Z								
otal (95% CI)		359		359	100.0%	0.81 [0.62, 1.07]	•	
otal events	69		85					
'otal events leterogeneity: Chi² = 1	1.67, df=		0.11); l² :	= 40%			0.01 0.1 1 10	10
otal events leterogeneity: Chi² = 1 est for overall effect: Z	1.67, df= (= 1.49 (P	= 0.14	0.11); I²⊧)		0.14). I² = 50	3.6%	0.01 0.1 1 10 Favours [ketamine] Favours [contro	
otal events leterogeneity: Chi² = 1 est for overall effect: Z	1.67, df= (= 1.49 (P rences: C	= 0.14 hi ^z = 2.	0.11); I²⊧)	(P = 1	0.14). I ^z = 53			
iotal events leterogeneity: Chi ^a = 1 lest for overall effect: Z est for subαroup differ <u>Study or Subgroup</u>	1.67, df = := 1.49 (P rences: C <u>Ketam</u> <u>Events</u>	= 0.14 hi ² = 2.	0.11); i² =) 15. df = 1 Contr	(P=) ol		3.6% (b)	Favours [ketamine] Favours [contro	
iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z iest for subdroup differ <u>Study or Subgroup</u> 4.1.1 Injection before	1.67, df = := 1.49 (P rences: C Ketam <u>Events</u> delivery	= 0.14 hi ^z = 2. ine <u>Total</u>	0.11); i² =) 15. df = 1 Contr	l (P = 1 ol Total	Weight M	3.6% (b) Risk Ratio -H, Random, 95% CI	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ^a = 1 lest for overall effect: Z est for subαroup differ <u>Study or Subgroup</u>	1.67, df = := 1.49 (P rences: C <u>Ketam</u> <u>Events</u>	= 0.14 hi ² = 2.	0.11); I ² =) 15. df = 1 <u>Contr</u> <u>Events</u>	(P=) ol		3.6% (b) Risk Ratio	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ² = 1 est for overall effect: Z iest for subaroup differ <u>Study or Subgroup</u> 4.1.1 Injection before Hassanein, A. 2015	1.67, df= (= 1.49 (P rences: C Ketam <u>Events</u> delivery 4	= 0.14 hi ² = 2. ine <u>Total</u> 45	0.11); I² ⊧) 15. df = 1 <u>Contr</u> <u>Events</u> 9	l (P = 1 ol <u>Total</u> 45	<u>Weight M</u> 10.6%	3.6% (b) Risk Ratio - <u>H, Random, 95% CI</u> 0.44 (0.15, 1.34)	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z iest for subdroup differ subdroup differ 4.1.1 Injection before Hassanein, A. 2015 Kose,E.A 2013 Lema, G. F.,2017 Menkiti, I. D 2012	1.67, df = (= 1.49 (P rences: C Ketam Events delivery 4 5	= 0.14 hi ^z = 2. ine <u>Total</u> 45 30 41 28	0.11); I² =) 15. df = 1 <u>Contr</u> <u>Events</u> 9 6	l (P = 1 ol <u>Total</u> 45 30 41 28	Weight M 10.6% 10.8% 10.6% 4.5%	3.6% (b) Risk Ratio <u>-H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.43] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 lest for overall effect. Z est for subdroup differ subdroup differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI)	1.67, df= (= 1.49 (P rences: C <u>Ketam Events</u> delivery 4 5 5 2	= 0.14 hi ² = 2. ine <u>Total</u> 45 30 41	0.11); I [™] =) 15. df = 1 Contr <u>Events</u> 9 6 6 1	l (P = 1 ol <u>Total</u> 30 41	Weight M 10.6% 10.8% 10.6%	3.6% (b) Risk Ratio -H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52]	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z est for suboroup differ suboroup differ 4.1.1 lnjection before Hassanein, A. 2015 Kose, E.A.2013 Lema, G. F.,2017 Menkit, I. D. 2012 Subtotal (95% CI) Total events	1.67, df = 1.49 (P rences: C Ketam <u>Events</u> delivery 4 5 2 2 16	ine 100 - 10	0.11); ᢪ=) 15. df = 1 Contr <u>Events</u> 9 6 6 1 1 22	ol Total 45 30 41 28 144	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%	3.6% (b) Risk Ratio <u>-H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.43] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 lest for overall effect. Z est for subdroup differ subdroup differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI)	1.67, df = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ²	ine Total 45 30 41 28 144 = 1.60,	0.11); ᢪ=) 15. df = 1 Events 9 6 1 22 df = 3 (P	ol Total 45 30 41 28 144	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%	3.6% (b) Risk Ratio <u>-H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.43] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82]	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z iest for suboroup differ Study or Subgroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkii, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d	1.67, df= = 1.49 (P rences: C Ketam <u>Events</u> delivery 4 5 5 2 16 0.00; Chi [≠] Z=1.01 (F	ine Total 45 30 41 28 144 = 1.60,	0.11); ᢪ=) 15. df = 1 Events 9 6 1 22 df = 3 (P	ol Total 45 30 41 28 144	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%	3.6% (b) Risk Ratio <u>-H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.43] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82]	Favours [ketamine] Favours [contro Risk Ratio	
iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z iest for suboroup differ Study or Subgroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotai (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d Edipoglu, I. S 2017	1.67, df= = 1.49 (P rences: C Ketam <u>Events</u> delivery 4 5 5 2 16 0.00; Chi [≈] Z = 1.01 (F elivery 2	= 0.14 hi [*] = 2. ine <u>Total</u> 45 30 41 28 144 = 1.60, P = 0.31	0.11); ₹ =) 15. df = 1 Contri Events 9 6 1 22 df = 3 (P) 11	l (P = 1 ol <u>Total</u> 45 30 41 28 144 = 0.66	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); I ² = 0% 8.2%	3.6% (b) Risk Ratio -H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.52] 2.00 [0.18, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect. Z cest for suboroup differ Study or Suboroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d Edipoglu, I. S 2017 Ma, J. H. 2019	1.67, df= = 1.49 (P rences: C Ketam <u>Events</u> delivery 4 5 2 16 0.00; chi ² Z = 1.01 (F elivery 2 62	= 0.14 hi [*] = 2. ine <u>Total</u> 45 30 41 28 144 = 1.60, ° = 0.31 60 327	0.11); ² =) 15. df = 1 <u>Contre</u> <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30	ol <u>Total</u> 45 30 41 28 144 = 0.66 60 327	Weight M 10.8% 10.8% 4.5% 36.6%); ² = 0% 8.2% 16.0%	3.6% (b) Risk Ratio <u>-H, Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.44] 0.83 [0.28, 2.62] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z lest for suboroup differ Study or Suboroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after de Edipoglu, I. S. 2017 Ra,J. H., 2019 Rahmanian, M. 2015	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 62 2 15	e = 0.14 hi ^z = 2. ine 45 30 41 28 144 e = 1.60, e = 0.31 60 327 80	0.11); ₹ = 15. df = 1 Contro Events 9 6 6 1 22 df = 3 (P) 11 30 28	(P = 1 ol <u>Total</u> 45 30 41 28 144 = 0.666 60 327 80	Weight M 10.6% 10.8% 4.5% 36.6%); ² = 0% 8.2% 16.0% 15.0%	3.6% (b) Risk Ratio -H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z lest for suboroup differ Study or Subgroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d Edipoglu, I. S 2017 Ma, J. H.2019 Rahmanian, M. 2015 Sarshivi, F2020	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 62 15 14	= 0.14 hi ^z = 2. ine 45 30 41 28 144 = 1.60, P = 0.31 60 327 80 45	0.11); ² =) 15. df = 1 <u>Contr</u> <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 8	(P = 1 ol 45 30 41 28 144 = 0.66 60 327 80 45	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); ² = 0% 8.2% 18.0% 15.0% 13.3%	3.6% (b) Risk Ratio .H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92] 1.75 [0.82, 3.76]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect. Z cest for subdroup differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after de Edipoglu, I. S 2017 Ma, J. H.2019 Rahmanian, M 2015 Sarshivi, F2020 Xu, Y 2017	1.67, df= = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 62 15 14 7	= 0.14 hi [≈] = 2. ine 45 300 41 28 144 = 1.60, ≥ = 0.31 60 327 80 45 162	0.11); [₽] =) 15. df = 1 <u>Contri- Events</u> 9 6 1 22 df = 3 (P) 11 30 28 8 2	(P = 1 ol 45 30 41 28 144 = 0.66 60 327 80 45 163	Weight M 10.6% 10.8% 4.5% 36.6%); I ² = 0% 8.2% 16.0% 15.0% 13.3%	3.6% (b) Risk Ratio <u>H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.23, 376] 3.52 [0.74, 16.70]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z lest for suboroup differ Study or Subgroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d Edipoglu, I. S 2017 Ma, J. H.2019 Rahmanian, M. 2015 Sarshivi, F2020	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 62 15 14	= 0.14 hi ^z = 2. ine 45 30 41 28 144 = 1.60, P = 0.31 60 327 80 45	0.11); ² =) 15. df = 1 <u>Contr</u> <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 8	(P = 1 ol 45 30 41 28 144 = 0.66 60 327 80 45	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); ² = 0% 8.2% 18.0% 15.0% 13.3%	3.6% (b) Risk Ratio .H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92] 1.75 [0.82, 3.76]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z lest for suboroub differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after de Edipoglu, I. S. 2017 Ma, J. H. 2019 Rahmanian, M. 2015 Sarshivi, F2020 Xu, Y. 2017 Yao, J. 2020	1.67, df= = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 62 15 14 7	= 0.14 hi ² = 2.	0.11); [₽] =) 15. df = 1 <u>Contri- Events</u> 9 6 1 22 df = 3 (P) 11 30 28 8 2	I (P = 1 ol <u>Total</u> 45 30 41 28 144 = 0.666 60 327 80 45 163 155	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); I ² = 0% 8.2% 16.0% 15.0% 13.3% 7.7% 3.2%	3.6% (b) Risk Ratio <u>-H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.33 [0.28, 2.44] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92] 1.75 [0.82, 3.76] 3.52 [0.74, 16.70] 9.12 [0.50, 167.90]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z lest for suboroup differ Study or Suboroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D 2012 Subtotal (95% CI) 1.2 Injection after de Edipoglu, I. S 2017 Ma, J. H.2019 Rahmanian, M 2015 Sarshivi, F2020 Xu, Y 2017 Yao, J 2020 Subtotal (95% CI)	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 62 62 15 14 7 4 104 0.04; Chi ²	$\begin{array}{l} = 0.14 \\ \text{ine} \\ \hline \\ \text{Total} \\ \\ 45 \\ 30 \\ 41 \\ 28 \\ 144 \\ \text{r} \\ 18 \\ 144 \\ \text{r} \\ 160 \\ 327 \\ 80 \\ 327 \\ 162 \\ 153 \\ 827 \\ \text{r} \\ \text{r} \\ 25.93 \\ \text{r} \\ \text{r} \\ \text{r} \\ \text{r} \\ 25.93 \\ \text{r} \\$	0.11); [₽] = 15. df = 1 Contrn <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 8 2 0 79 9, df = 5 (0)	l (P = 1 ol <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>100</u> <u>1</u>	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); ² = 0% 8.2% 16.0% 15.0% 15.0% 15.3% 7.7% 3.2% 63.4%	3.6% (b) Risk Ratio <u>H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.62] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.73, 3.11] 0.52 [0.74, 16.70] 9.12 [0.50, 187, 90] 1.23 [0.54, 2.78]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 cest for overall effect: Z est for suboroup differ Study or Suboroup 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after d Edipoglu, I. S 2017 Ma, J. H. 2019 Rahmanian, M. 2015 Sarshivi, F2020 Xu, Y. 2017 Yao, J. 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 62 62 15 14 7 4 104 0.04; Chi ²	$\begin{array}{l} = 0.14 \\ \text{ine} \\ \hline \\ \text{Total} \\ \\ 45 \\ 30 \\ 41 \\ 28 \\ 144 \\ \text{r} \\ 18 \\ 144 \\ \text{r} \\ 160 \\ 327 \\ 80 \\ 327 \\ 162 \\ 153 \\ 827 \\ \text{r} \\ \text{r} \\ 25.93 \\ \text{r} \\ \text{r} \\ \text{r} \\ \text{r} \\ 25.93 \\ \text{r} \\$	0.11); [₽] = 15. df = 1 Contrn <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 8 2 0 79 9, df = 5 (0)	(P = 1 Total 45 30 41 28 144 60 327 80 45 165 830 P < 0.0	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); ² = 0% 8.2% 16.0% 15.0% 15.0% 15.3% 7.7% 3.2% 63.4%	3.6% (b) Risk Ratio <u>H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.62] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.73, 3.11] 0.52 [0.74, 16.70] 9.12 [0.50, 187, 90] 1.23 [0.54, 2.78]	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 lest for overall effect Z lest for subdroup differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after de Edipoglu, I. S. 2017 Ma, J. H.2019 Rahmanian, M. 2015 Sarshivi, F2020 Xu, Y. 2017 Yao, J. 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect.	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 62 62 15 14 7 4 104 0.04; Chi ²	= 0.14, hi ² = 2.	0.11); [≠] = 15. df = 1 Contrn <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 8 2 0 79 9, df = 5 (0)	(P = 1 Total 45 30 41 28 144 60 327 80 45 165 830 P < 0.0	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); ² = 0% 8.2% 16.0% 15.0% 13.3% 7.7% 3.2% 63.4% 001); ² = 81	3.6% (b) Risk Ratio .H. Random, 95% CI 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92] 1.75 [0.82, 3.76] 3.52 [0.74, 16.70] 9.12 [0.50, 167.90] 1.23 [0.54, 2.78] %	Favours [ketamine] Favours [contro Risk Ratio	
otal events leterogeneity: Chi ² = 1 lest for overall effect: Z lest for suboroub differ Study or Suboroub differ 4.1.1 Injection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 Injection after de Edipoglu, I. S. 2017 Ma, J. H.2019 Rahmanian, M. 2015 Sarshivi, F2020 Xu, Y. 2017 Yao, J. 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. Total events Heterogeneity: Tau ² = Total events Heterogeneity: Tau ² =	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 2 16 0.00; Chi ² Z = 1.01 (F elivery 2 155 14 7 4 104 0.69; Chi ² Z = 0.50 (F 120 0.50; Chi ²	= 0.14, hi ² = 2: ine Total 45 30 41 28 144 5 = 1.60, 2° = 0.31 60 327 53 77 827 5 827 971 5 30 2° = 0.52 971	0.11); ² = 15. df = 1 Contro <u>Events</u> 9 6 8 1 22 df = 3 (P 1 30 28 8 2 0 79 9, df = 5 (0) 101 8, df = 9 (0)	(P = Total 45 30 41 28 144 = 0.666 60 327 80 45 163 155 830 P < 0.0 974	Weight M 10.6% 10.8% 10.6% 4.5% 36.6%); I* = 0% 8.2% 16.0% 15.0% 13.3% 7.7% 63.4% 001); I* = 81 100.0%	3.6% (b) Risk Ratio <u>H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.33 [0.28, 2.44] 0.33 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.92] 1.75 [0.82, 3.76] 9.12 [0.50, 167.90] 1.23 [0.54, 2.78] % 1.03 [0.58, 1.83]	Favours [ketamine] Favours [contro	
iotal events leterogeneity: Chi ² = 1 lest for overall effect. Z lest for subaroub differ 4.1.1 lnjection before Hassanein, A. 2015 Kose, E.A. 2013 Lema, G. F., 2017 Menkiti, I. D. 2012 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect. 4.1.2 lnjection after de Edipoglu, I. S. 2017 Ma, J. H.2019 Rahmanian, M. 2015 Sarshivi, F2020 Xu, Y. 2017 Yao, J. 2020 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect.	1.67, df = = 1.49 (P rences: C Ketam Events delivery 4 5 5 2 16 0.00; Chi ² Z = 1.01 (f elivery 2 62 15 14 7 4 0.69; Chi ² Z = 0.50 (F 120 0.50; Chi ² Z = 0.10 (f	= 0.14, hi ² = 2: ine Total 45 300 41 28 144 = 1.60, 2 = 0.31 60 327 80 0 = 0.31 153 827 = 25.93 971 = 30.38 2 = 0.92	0.11); ² =) 15. df = 1 Contri- <u>Events</u> 9 6 6 1 22 df = 3 (P) 11 30 28 2 0 79 9, df = 5 (1) 101 9, df = 9 (1)	(P = 1 1 (P = 1 1 (P = 1 1 (P = 1) 1 (P	Weight M 10.6% 10.8% 10.8% 4.5% 36.6% 36.6% 16.0% 15.0% 13.3% 63.4% 001); I* = 81 100.0% 004); I* = 70 100.4%	3.6% (b) Risk Ratio <u>H. Random, 95% CI</u> 0.44 [0.15, 1.34] 0.83 [0.28, 2.44] 0.83 [0.28, 2.52] 2.00 [0.19, 20.82] 0.73 [0.40, 1.34] 0.18 [0.04, 0.79] 2.07 [1.37, 3.11] 0.54 [0.31, 0.74, 16.70] 9.12 [0.50, 187, 90] 1.23 [0.54, 2.78] % 1.03 [0.58, 1.83]	Favours [ketamine] Favours [contro Risk Ratio	

Figure 6. Forest plot of subgroups [12–23]: (a) headaches; (b) nausea; (c) vomiting.




Figure 7. Funnel plot of comparison: (a) headaches; (b) nausea; (c) vomiting.

4. Discussion

A cesarean section is one of the most common operations in the operating room, and spinal anesthesia can provide sufficient surgical anesthesia [24]. Among the many complications of spinal anesthesia, post-dural puncture headaches are one of the more common, usually due to cerebrospinal fluid flowing out of the patient's dural puncture site [25,26]. Moreover, due to significant weight gain during pregnancy, most pregnant women have thickened subcutaneous fat, making the administration of spinal anesthesia more difficult, which also leads to an increased risk of cerebrospinal fluid outflow leading to hypocranial pressure [27,28]. Headaches are a characteristic symptom of low intracranial pressure [29], most importantly, postural headaches, accompanied by nausea and vomiting [30]. Therefore, we regard the incidence of headaches, nausea, and vomiting as an indicator for assessing the treatment of hypocranial pressure. Studies have shown that hypocranial pressure syndrome affects the prognosis and recovery of pregnant women [31]. Although different treatment modalities are available depending on the severity, including lying down, massive fluid administration, analgesic medications, and epidural blood patches [32,33], the effective prevention of PDPH is important.

Ketamine is a traditional intravenous anesthetic that not only has sympathetic excitatory effects [34], but also increases cerebral blood flow by dilating cerebral blood vessels, triggering an increase in intracranial pressure [35]. The mechanism by which ketamine increases intracranial pressure has been discerned, and it is noteworthy that ketamine can cause an increase in intracranial pressure by increasing the partial pressure of carbon dioxide and thus dilating the cerebral vasculature while preserving natural respiration [36]. Therefore, the intracranial pressure-raising effect of ketamine was allowed during spontaneous breathing in the cesarean section patients included in our study. Furthermore, although other studies have suggested that ketamine may cause a decrease in intracranial pressure [37,38] or have no significant effect on intracranial pressure [36,39,40], the prevailing view remains that ketamine has an increased effect on intracranial pressure. However, it is unclear whether this increase in intracranial pressure is sustained and whether it has associated adverse effects in the perioperative period.

In this meta-analysis, we demonstrate that intravenous ketamine does not improve headaches, nausea, and vomiting due to low cranial pressure in patients undergoing spinal anesthesia for cesarean delivery. Considering that the different time points of intravenous ketamine administration may be a key variable in this assessment, we performed a subgroup analysis with fetal delivery as the dividing line, but no difference between the ketamine and control groups was demonstrated. We concluded that the different time points of administration had no effect on the therapeutic effect of ketamine.

The main limitation of this study is that, for most of the included studies, we do not know whether the patients experienced cerebrospinal fluid leakage—this would affect our ability to accurately determine whether these patients had low cranial pressure. Thus, we could not distinguish whether the patients' headaches, nausea, and vomiting were caused by low cranial pressure or the psychiatric-related side effects of ketamine [41,42]. Therefore, based on the available evidence, we believe that ketamine (range 0.15 mg/kg to 0.5 mg/kg) is not effective in preventing hypocranial-pressure-related symptoms in patients undergoing cesarean section under spinal anesthesia. However, esketamine, with its stronger analgesic effect and fewer psychiatric side effects, has gradually replaced ketamine in clinical anesthesia [43]. This drug may be an effective agent for the prevention of hypocranial pressure.

Author Contributions: Conceptualization, X.L.; methodology, X.L.; software, X.L. and S.L.; validation, X.L., X.Y. and Y.Z.; formal analysis, X.L.; investigation, Z.D.; resources, X.L. and X.Y; data curation, X.L.; writing—original draft preparation, X.L.; writing—review and editing, X.L., X.Y. and S.L.; supervision, C.H. and Q.G.; project administration, C.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

1. Search strategy for CENTRAL, the Cochrane Library

#1 Mesh descriptor: [Cesarean Section] explode all trees#2 Mesh descriptor: [Ketamine] explode all trees#3 (Spinal anesthesia): ti, ab, kw OR (Epidural): ti, ab, kw#4 (#1 AND #2 AND #3)

2. Search strategy for web of science (OvidSP)

#1 TS= (Ketamine OR CI-581 OR CI581 OR CI581 OR Ketalar OR Ketaset OR Ketanest OR Calipsol OR Kalipsol OR Kalipsol OR Ketamine Hydrochloride)

#2 TS= (Cesarean section OR cesarean Sections OR Delivery, Abdominal OR Abdominal Deliveries OR Deliveries, Abdominal OR Caesarean Section OR Caesarean Sections OR Abdominal Delivery OR C-Section OR C Section OR Postcesarean Section)

#3 TS= (Anesthesia, Epidural OR Anesthesia, Peridural OR Anesthesia, Peridural OR Peridural Anesthesia OR Peridural Anesthesia's OR Anesthesia, Extradural OR Anesthesia, Extradural OR Extradural Anesthesia OR Extradural Anesthesia's OR Epidural Anesthesia OR Anesthesias, Epidural OR Epidural Anesthesias)

10 of 12

#4 TS= (Anesthesia, Spinal OR Anesthesia, Spinal OR Spinal Anesthesia OR Spinal Anesthesias) #5'#4 OR #3'

#6'#5 AND #2 AND #1'

- 3. Search strategy for Embase (OvidSP)
 - #1 ('controlled study': ab, ti OR random*: ab, ti OR 'trial*: ab, ti)
 - #2 ('ketamine'/exp)
 - #3 (keta*: ab, ti)
 - #4 (#2 AND #3)
 - #5 ('cesarean section'/exp)
- #6 ('cesarean section*': ab, it OR deliver*: ab, it OR 'abdominal deliver*': ab, ti OR 'c section*': ab, ti OR 'postcesarean section': ab, ti OR cesarean: ab, ti)
 - #7 (#5 AND #6)
 - #8 (#1 AND #4 AND #7)
- 4. Search strategy for MEDLINE (OvidSP)
 - #1 ("ketamine"[Mesh Terms] OR "keta*"[Mesh Terms])

#2 ("cesarean section*"[Title/Abstract] OR "deliver*"[Title/Abstract] OR "abdominal deliver*"[Title/Abstract] OR "c section*"[Title/Abstract] OR "postcesarean section" [Title/Abstract] OR "cesarean section"[Mesh Terms])

#3 ("Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial"
[Publication Type] OR "Clinical Trials as Topic" [Mesh Terms: noexp] OR "randomized"
[Title/Abstract] OR "placebo" [Title/Abstract] OR "randomly" [Title/Abstract] OR "trial"
[Title/Abstract]) NOT ("Animals" [Mesh Terms] NOT "Humans" [Mesh Terms])
#4 (#1 AND #2 AND #3)

References

- Belizán, J.M.; Minckas, N.; McClure, E.M.; Saleem, S.; Moore, J.L.; Goudar, S.S.; Esamai, F.; Patel, A.; Chomba, E.; Garces, A.L.; et al. An approach to identify a minimum and rational proportion of caesarean sections in resource-poor settings: A global network study. *Lancet Glob. Health* 2018, 6, e894–e901. [CrossRef]
- Stjernholm, Y.; Petersson, K.; Eneroth, E. Changed indications for cesarean sections. Acta Obstet. Gynecol. Scand. 2010, 89, 49–53. [CrossRef] [PubMed]
- 3. Gregory, K.D.; Curtin, S.C.; Taffel, S.M.; Notzon, F.C. Changes in indications for cesarean delivery: United States, 1985 and 1994. *Am. J. Public Health* **1998**, *88*, 1384–1387. [CrossRef]
- Mylonas, I.; Friese, K. Indications for and Risks of Elective Cesarean Section. Dtsch. Arztebl. Int. 2015, 112, 489–495. [CrossRef] [PubMed]
- 5. Butwick, A.; Carvalho, B.; Danial, C.; Riley, E. Retrospective analysis of anesthetic interventions for obese patients undergoing elective cesarean delivery. *J. Clin. Anesth.* 2010, 22, 519–526. [CrossRef]
- Ferede, Y.A.; Nigatu, Y.A.; Agegnehu, A.F.; Mustofa, S.Y. Incidence and associated factors of post dural puncture headache after cesarean section delivery under spinal anesthesia in University of Gondar Comprehensive Specialized Hospital, 2019, cross sectional study. *Int. J. Surg. Open* 2021, 33, 100348. [CrossRef]
- Gaiser, R.R. Postdural Puncture Headache: An Evidence-Based Approach. Anesthesiol. Clin. 2017, 35, 157–167. [CrossRef] [PubMed]
- D'Antona, L.; Merchan MA, J.; Vassiliou, A.; Watkins, L.D.; Davagnanam, I.; Toma, A.K.; Matharu, M.S. Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome: A Systematic Review and Meta-analysis. JAMA Neurol. 2021, 78, 329–337. [CrossRef] [PubMed]
- 9. Porter, S.B. Perioperative ketamine for acute analgesia and beyond. Rom. J. Anaesth. Intensiv. Care 2019, 26, 67–73.
- Gardner, A.; Olson, B.; Lichtiger, M.J.A. Cerebrospinal-fluid pressure during dissociative anesthesia with ketamine. *Anesthesiology* 1971, 35, 226–228. [CrossRef]
- 11. Wyte, S.; Shapiro, H.M.; Turner, P.; Harris, A.B. Ketamine-induced intracranial hypertension. *Anesthesiology* **1972**, *36*, 174–176. [CrossRef] [PubMed]
- 12. Zangouei, A.; Zahraei, S.A.H.; Sabertanha, A.; Nademi, A.; Golafshan, Z.; Zangoue, M. Effect of low-dose intravenous ketamine on prevention of headache after spinal anesthesia in patients undergoing elective cesarean section: A double-blind clinical trial study. *Anesthesiol. Pain Med.* **2019**, *9*, e97249. [CrossRef]
- Sen, S.; Ozmert, G.; Aydin, O.N.; Baran, N.; Calskan, E. The persisting analgesic effect of low-dose intravenous ketamine after spinal anaesthesia for caesarean section. *Eur. J. Anaesthesiol.* 2005, 22, 518–523. [CrossRef] [PubMed]

- 14. Menkiti, I.D.; Desalu, I.; Kushimo, O.T. Low-dose intravenous ketamine improves postoperative analgesia after caesarean delivery with spinal bupivacaine in African parturients. *Int. J. Obstet. Anesth.* **2012**, *21*, 217–221. [CrossRef] [PubMed]
- Rahmanian, M.; Leysi, M.; Hemmati, A.A.; Mirmohammadkhani, M. The effect of low-dose intravenous ketamine on postoperative pain following cesarean section with spinal anesthesia: A randomized clinical trial. *Oman Med. J.* 2015, 30, 11–16. [CrossRef]
- 16. Edipoglu, I.S.; Celik, F.S.; Omaygenc, D.O. Perioperative low-dose ketamine diminishes post-operative caesarean pain, nausea & vomiting after spinal anaesthesia. J. Istanb. Fac. Med.-Istanb. Tip Fak. Derg. 2017, 80, 7–12.
- 17. Xu, Y.; Li, Y.; Huang, X.; Chen, D.; She, B.; Ma, D. Single bolus low-dose of ketamine does not prevent postpartum depression: A randomized, double-blind, placebo-controlled, prospective clinical trial. *Arch. Gynecol. Obstet.* **2017**, 295, 1167–1174. [CrossRef]
- Yao, J.; Song, T.; Zhang, Y.; Guo, N.; Zhao, P. Intraoperative ketamine for reduction in postpartum depressive symptoms after cesarean delivery: A double-blind, randomized clinical trial. *Brain Behav.* 2020, 10, e01715. [CrossRef]
- 19. Kose, E.A.; Honca, M.; Dal, D.; Akinci, S.B.; Aypar, U. Prophylactic ketamine to prevent shivering in parturients undergoing Cesarean delivery during spinal anesthesia. *J. Clin. Anesth.* **2013**, 25, 275–280. [CrossRef]
- 20. Hassanein, A.; Mahmoud, E. Effect of low dose ketamine versus dexamethasone on intraoperative nausea and vomiting during cesarean section under spinal anesthesia. *Egypt. J. Anaesth.* **2015**, *31*, 59–63. [CrossRef]
- Lema, G.F.; Gebremedhn, E.G.; Gebregzi, A.H.; Desta, Y.T.; Kassa, A.A. Efficacy of intravenous tramadol and low-dose ketamine in the prevention of post-spinal anesthesia shivering following cesarean section: A double-blinded, randomized control trial. *Int. J. Womens Health* 2017, *9*, 681–688. [CrossRef] [PubMed]
- Ma, J.H.; Wang, S.-Y.; Yu, H.-Y.; Li, D.-Y.; Luo, S.-C.; Zheng, S.-S.; Wan, L.-F.; Duan, K.-M. Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section. *Psychiatry Res.* 2019, 279, 252–258. [CrossRef] [PubMed]
- 23. Sarshivi, F.; Ghaderi, E.; Sarshivi, A.; Shami, S.; Nasseri, K. Intravenous ketamine for the prevention of post anesthetic shivering in spinal anesthesia: A randomized double-blind placebo-controlled trial. *Acta Med. Iran.* **2020**, *58*, 479–485. [CrossRef]
- Sachs, A.; Smiley, R. Post-dural puncture headache: The worst common complication in obstetric anesthesia. *Semin. Perinatol.* 2014, *38*, 386–394. [CrossRef]
- 25. Grände, P.O. Mechanisms behind postspinal headache and brain stem compression following lumbar dural puncture—A physiological approach. *Acta Anaesthesiol. Scand.* **2005**, *49*, 619–626. [CrossRef] [PubMed]
- 26. Davignon, K.R.; Dennehy, K.C. Update on postdural puncture headache. Int. Anesthesiol. Clin. 2002, 40, 89–102. [CrossRef]
- 27. Antoine, C.; Young, B.K. Cesarean section one hundred years 1920–2020: The Good, the Bad and the Ugly. *J. Perinat. Med.* 2020, 49, 5–16. [CrossRef]
- Kuntz, K.; Kokmen, E.; Stevens, J.C.; Miller, P.; Offord, K.P.; Ho, M.M. Post-lumbar puncture headaches: Experience in 501 consecutive procedures. *Neurology* 1992, 42, 1884. [CrossRef]
- Brownridge, P. The management of headache following accidental dural puncture in obstetric patients. *Anaesth. Intensiv. Care* 1983, 11, 4–15. [CrossRef]
- 30. Haider, A.; Sulhan, S.; Watson, I.T.; Leonard, D.; Arrey, E.N.; Khan, U.; Nguyen, P.; Layton, K.F. Spontaneous Intracranial Hypotension Presenting as a "Pseudo-Chiari 1". *Cureus* 2017, 9, e1034. [CrossRef]
- 31. Angle, P.; Thompson, D.; Szalai, J.P.; Tang, S.L.T. Expectant management of postdural puncture headache increases hospital length of stay and emergency room visits. *Can. J. Anaesth.* **2005**, *52*, 397–402. [CrossRef] [PubMed]
- International Headache Society. Headache classification subcommittee of the international headache society. Cephalgia 2004, 24, 9–160.
- Ahmed, S.; Jayawarna, C.; Jude, E. Post lumbar puncture headache: Diagnosis and management. *Postgrad. Med. J.* 2006, 82, 713–716. [CrossRef] [PubMed]
- 34. Dakwar, E.; Levin, F.; Foltin, R.W.; Nunes, E.V.; Hart, C.L. The Effects of Subanesthetic Ketamine Infusions on Motivation to Quit and Cue-Induced Craving in Cocaine-Dependent Research Volunteers. *Biol. Psychiatry* **2014**, *76*, 40–46. [CrossRef] [PubMed]
- 35. Sari, A.; Okuda, Y.; Takeshita, H. The effect of ketamine on cerebrospinal fluid pressure. *Anesth. Analg.* **1972**, *51*, 560–565. [CrossRef]
- Himmelseher, S.; Durieux, M.E. Revising a dogma: Ketamine for patients with neurological injury? *Anesth. Analg.* 2005, 101, 524–534. [CrossRef]
- Zeiler, F.; Teitelbaum, J.; West, M.; Gillman, L.M. The ketamine effect on intracranial pressure in nontraumatic neurological illness. J. Crit. Care 2014, 29, 1096–1106. [CrossRef]
- 38. Godoy, D.; Badenes, R.; Pelosi, P.; Robba, C. Ketamine in acute phase of severe traumatic brain injury "an old drug for new uses?". *Crit. Care* **2021**, 25, 19. [CrossRef]
- Albanese, J.; Arnaud, S.; Rey, M.; Thomachot, L.; Alliez, B.; Martin, C. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. *Anesthesiology* 1997, 87, 1328–1334. [CrossRef]
- 40. Cohen, L.; Athaide, V.; Wickham, M.E.; Doyle-Waters, M.M.; Rose, N.G.; Hohl, C.M. The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: A systematic review. *Ann. Emerg. Med.* **2015**, *65*, 43–51.e2. [CrossRef]
- Morgan, C.J.; Mofeez, A.; Brandner, B.; Bromley, L.; Curran, H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. *Neuropsychopharmacology* 2004, 29, 208–218. [CrossRef] [PubMed]

- Wan, L.B.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Iosifescu, D.V.; Chang, L.C.; Foulkes, A.; Mathew, S.J.; Charney, D.S.; Murrough, J.W. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. *J. Clin. Psychiatry* 2015, 76, 247–252. [CrossRef] [PubMed]
- Wang, J.; Huang, J.; Yang, S.; Cui, C.; Ye, L.; Wang, S.-Y.; Yang, G.-P.; Pei, Q. Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. Drug. Des. Dev. Ther. 2019, 13, 4135–4144. [CrossRef] [PubMed]